Article Details
Retrieved on: 2022-04-18 18:52:01
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NEW YORK – Kinnate Biopharma announced today that it has begun dosing patients in a Phase I trial of its small molecule kinase inhibitor KIN-3248.
Article found on: www.precisiononcologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here